252 related articles for article (PubMed ID: 22851637)
21. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
22. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
Erchegyi J; Penke B; Simon L; Michaelson S; Wenger S; Waser B; Cescato R; Schaer JC; Reubi JC; Rivier J
J Med Chem; 2003 Dec; 46(26):5587-96. PubMed ID: 14667213
[TBL] [Abstract][Full Text] [Related]
23. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
24. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of
Zhu W; Cheng Y; Jia R; Zhao H; Bai C; Xu J; Yao S; Huo L
J Nucl Med; 2021 Oct; 62(10):1398-1405. PubMed ID: 33579804
[No Abstract] [Full Text] [Related]
25. Radiolabeled bicyclic somatostatin-based analogs: a novel class of potential radiotracers for SPECT/PET of neuroendocrine tumors.
Fani M; Mueller A; Tamma ML; Nicolas G; Rink HR; Cescato R; Reubi JC; Maecke HR
J Nucl Med; 2010 Nov; 51(11):1771-9. PubMed ID: 20956465
[TBL] [Abstract][Full Text] [Related]
26. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
27. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.
Reubi JC; Schär JC; Waser B; Wenger S; Heppeler A; Schmitt JS; Mäcke HR
Eur J Nucl Med; 2000 Mar; 27(3):273-82. PubMed ID: 10774879
[TBL] [Abstract][Full Text] [Related]
28. Design, preparation and biological evaluation of a
Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
[TBL] [Abstract][Full Text] [Related]
29. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
30. A new
Mansi R; Abid K; Nicolas GP; Del Pozzo L; Grouzmann E; Fani M
EJNMMI Res; 2020 Aug; 10(1):90. PubMed ID: 32757150
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a New
Mansi R; Nicolas GP; Del Pozzo L; Abid KA; Grouzmann E; Fani M
Molecules; 2020 Sep; 25(18):. PubMed ID: 32932783
[TBL] [Abstract][Full Text] [Related]
32. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging.
Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR
J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125
[TBL] [Abstract][Full Text] [Related]
33. Comparative study on DOTA-derivatized bombesin analog labeled with 90Y and 177Lu: in vitro and in vivo evaluation.
Koumarianou E; Mikołajczak R; Pawlak D; Zikos X; Bouziotis P; Garnuszek P; Karczmarczyk U; Maurin M; Archimandritis SC
Nucl Med Biol; 2009 Aug; 36(6):591-603. PubMed ID: 19647165
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
[TBL] [Abstract][Full Text] [Related]
35. Somatostatin receptor targeting with hydrophilic [
Makris G; Kuchuk M; Gallazzi F; Jurisson SS; Smith CJ; Hennkens HM
Nucl Med Biol; 2019 Apr; 71():39-46. PubMed ID: 31129499
[TBL] [Abstract][Full Text] [Related]
36. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog.
Reubi JC; Erchegyi J; Cescato R; Waser B; Rivier JE
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1551-8. PubMed ID: 20396884
[TBL] [Abstract][Full Text] [Related]
37. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.
Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
Eur J Med Chem; 2014 Feb; 73():30-7. PubMed ID: 24378707
[TBL] [Abstract][Full Text] [Related]
38. Comparison of
Krebs S; O'Donoghue JA; Biegel E; Beattie BJ; Reidy D; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; Pandit-Taskar N
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3047-3057. PubMed ID: 32378020
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]